1. Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas
   Zhaoxia Li et al, 2023, Frontiers in Oncology CrossRef
2. The factors associated with the early diagnosis of nasal NK/T-cell lymphoma with prominent ocular symptoms and general nasal NKTL
   Zhen zhen Hu et al, 2019, American Journal of Otolaryngology CrossRef
3. Prognostic Nomogram for Overall Survival in Early Stage Extranodal Natural Killer/T Cell Lymphoma Treated With High-Dose Radiotherapy
   Luo Huang et al, 2020, Clinical Lymphoma Myeloma and Leukemia CrossRef
4. Anti-CD30 antibody–drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives
   H. Miles Prince et al, 2023, Annals of Hematology CrossRef
5. Indolent CD30-Positive Extranodal NK/T Cell Lymphoma with Large Cell Transformation: Case Report and Literature Review
   Pengyi Yu et al, 2022, Indian Journal of Otolaryngology and Head & Neck Surgery CrossRef
6. Brentuxinmab vedotin, alone or combine with bendamustine in the treatment of natural killer T cell lymphoma
   Ping Zhang et al, 2022, Hematological Oncology CrossRef
7. The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas
   Kennosuke Karube et al, 2021, Expert Review of Hematology CrossRef
8. A retrospective study on the clinicopathological and molecular features of 22 cases of natural killer/T-cell lymphoma in children and adolescents
   Guan‑Nan Wang et al, 2022, Scientific Reports CrossRef
9. Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas
   Teresa Poggio et al, 2018, Cancers CrossRef
10. CD30 Is Highly Expressed in Chronic Obstructive Pulmonary Disease and Induces the Pulmonary Vascular Remodeling
    Liang Luo et al, 2018, BioMed Research International CrossRef